Therefore, this study extensively explored the copy number variation, clinical feature relationship, TME and immune infiltration of CRGs in HCC at the transcriptome level, single-cell level and network pharmacology level and revealed that GCLM and BEX1 may be potential therapeutic targets mediating cuproptosis in HCC. Here, BEX1 is linked to hepatocellular carcinoma.